Literature DB >> 12067969

Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion.

Anita Lal1, Chad A Glazer, Holly M Martinson, Henry S Friedman, Gary E Archer, John H Sampson, Gregory J Riggins.   

Abstract

The gene most commonly altered in human glioblastomas is the epidermalgrowth factor receptor (EGFR). We profiled transcripts induced by mutantEGFR to better understand its role in tumor progression. The pattern found suggested enhanced tumor invasion. The highly induced genes included extracellular matrix components, metalloproteases, and a serine protease. We confirmed that mutant EGFR did make glioblastoma cells both more motile and invasive using in vitro assays. Furthermore, inhibitors of EGFR (OSI-774 and Tyrphostin AG1478) selectively down-regulated these molecular effectors in glioblastoma cells, eliminating enhanced invasion.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12067969

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  100 in total

1.  Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

Authors:  John H Sampson; Amy B Heimberger; Gary E Archer; Kenneth D Aldape; Allan H Friedman; Henry S Friedman; Mark R Gilbert; James E Herndon; Roger E McLendon; Duane A Mitchell; David A Reardon; Raymond Sawaya; Robert J Schmittling; Weiming Shi; James J Vredenburgh; Darell D Bigner
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

Review 2.  Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?

Authors:  Santiago Rivera; Michel Khrestchatisky; Leszek Kaczmarek; Gary A Rosenberg; Diane M Jaworski
Journal:  J Neurosci       Date:  2010-11-17       Impact factor: 6.167

3.  3,3'-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutants.

Authors:  Massod Rahimi; Kai-Ling Huang; Careen K Tang
Journal:  Cancer Lett       Date:  2010-03-17       Impact factor: 8.679

Review 4.  Exploiting the curative potential of adoptive T-cell therapy for cancer.

Authors:  Christian S Hinrichs; Steven A Rosenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 5.  HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.

Authors:  Jeffrey J Raizer
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

6.  Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization.

Authors:  Mirko H H Schmidt; Frank B Furnari; Webster K Cavenee; Oliver Bögler
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-06       Impact factor: 11.205

7.  EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors.

Authors:  Li Li; Amalia Dutra; Evgenia Pak; Joseph E Labrie; Rachel M Gerstein; Pier Paolo Pandolfi; Larry D Recht; Alonzo H Ross
Journal:  Neuro Oncol       Date:  2008-09-23       Impact factor: 12.300

8.  Tumorigenicity of cortical astrocyte cell line induced by the protease ADAM17.

Authors:  Mark Katakowski; Feng Jiang; XuGuang Zheng; Jorge A Gutierrez; Alexandra Szalad; Michael Chopp
Journal:  Cancer Sci       Date:  2009-05-18       Impact factor: 6.716

9.  Identification of cell surface targets through meta-analysis of microarray data.

Authors:  Henry Haeberle; Joel T Dudley; Jonathan T C Liu; Atul J Butte; Christopher H Contag
Journal:  Neoplasia       Date:  2012-07       Impact factor: 5.715

10.  EGFR signaling downstream of EGF regulates migration, invasion, and MMP secretion of immortalized cells derived from human ameloblastoma.

Authors:  Marina Rolo Pinheiro da Rosa; Aline Semblano Carreira Falcão; Hellen Thais Fuzii; Maria Sueli da Silva Kataoka; André L R Ribeiro; Enrique Boccardo; Adriane Sousa de Siqueira; Ruy G Jaeger; João de Jesus Viana Pinheiro; Sérgio de Melo Alves Júnior
Journal:  Tumour Biol       Date:  2014-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.